Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

NCT00385580 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT00385580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00385580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2007
Completion date
October 31, 2010
Enrollment
94 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer